1. The ability of aminoguanidine, an inhibitor of collagen cross-linking, to prevent changes in cardiac and vascular structure and function has been determined in the DOCA-salt hypertensive rat as a model of the cardiovascular remodelling observed in chronic human hypertension.
2. Uninephrectomised rats (UNX) administered DOCA (25mg every 4th day sc) and 1% NaCl in drinking water for 28 days developed cardiovascular remodelling shown as systolic hypertension, left ventricular hypertrophy, increased thoracic aortic and left ventricular wall thickness, increased left ventricular inflammatory cell infiltration together with increased interstitial collagen and increased passive diastolic stiffness, impaired contractility, prolongation of the action potential duration and vascular dysfunction.
3. Treatment with aminoguanidine (0.05 -0.1% in drinking water; average 182±17 mg kg -1 day -1 in DOCA-salt rats) decreased blood pressure (DOCA-salt 176±4; + aminoguanidine 144±5*mmHg; *P<0.05 vs DOCA-salt), decreased left ventricular wet weights (DOCA-salt 3.17±0.07; + aminoguanidine 2.66±0.08*mg g -1 body wt), reduced diastolic stiffness constant (DOCA-salt 30.1±1.2; + aminoguanidine 24.3±1.2* (dimensionless)), improved cardiac contractility (DOCA-salt 1610±130; + aminoguanidine 2370±100*mmHg s -1 ) and vascular reactivity (3.4-fold* increase in maximal contractile response to noradrenaline, 3.2-fold* increase in maximal relaxation response to acetylcholine, 2-fold* increase in maximal relaxation response to sodium nitroprusside) and prolonged the action potential duration at 50% repolarization without altering collagen content or inflammatory cell infiltration.
4. Thus, cardiovascular function in DOCA-salt hypertensive rats can be improved by aminoguanidine independent of changes in collagen content. This suggests that collagen cross-linking is an important cause of cardiovascular dysfunction during cardiovascular remodelling in hypertension.
INTRODUCTION
Cardiovascular remodelling in chronic hypertension involves ventricular hypertrophy, interstitial and perivascular fibrosis, electrical remodelling in the heart and endothelial dysfunction. The importance of the increased collagen deposition in cardiovascular dysfunction has long been recognised (Weber et al., 1993) with recent studies investigating the role of relevant mediators such as angiotensin II (Sun et al., 2004) . Collagen cross-linking may be a more important determinant of the increased ventricular stiffness in hypertensive rats than collagen content (Norton et al., 1997) ; collagen cross-linking was increased in the DOCA-salt hypertensive rat (Ooshima & Midorikawa, 1977 ). An increased collagen crosslinking has been proposed as the major cause of the increased arterial wall stiffness and decreased myocardial compliance during ageing (Lakatta, 1993; Li et al., 1996; Cantini et al., 2001) . The formation of cross-links on long-lived matrix components follows non-enzymic reactions between glucose and proteins to form advanced glycation end-products (AGEs) (Brownlee, 1995) . These products are markedly increased in ageing and diabetic rats (Brownlee, 1995) . Increased AGE formation has also been shown in the aorta of stroke-prone Spontaneously Hypertensive Rats (SHRs) (Mizutani et al., 2002) . Further, methylglyoxal (the highly reactive dicarbonyl precursor of AGEs), AGEs, oxidised glutathione and oxidative stress were significantly higher in vascular smooth muscle cells from 12 week old SHR compared with age-matched normotensive Wistar-Kyoto rats (Wu & Juurlink, 2002) . In 5 week old stroke-prone SHR, OPB-9195, an inhibitor of AGE formation, lowered systolic blood pressure and glycated albumin concentrations (Mizutani et al., 2002) .
The nucleophilic hydrazine, aminoguanidine, is an effective inhibitor of AGE formation thus slowing or preventing age-related aortic stiffening and cardiac hypertrophy in rats (Li et al., 1996; Corman et al., 1998) . Further, aminoguanidine is a selective inhibitor of inducible NO synthase (Nilsson, 1999) and may quench hydroxyl radicals and inhibit free radical formation, lipid peroxidation and oxidant induced apoptosis (Giardino et al., 1998) . In rats, aminoguanidine ameliorated the neuropathic, ocular and cardiac complications of diabetes (Miyauchi et al., 1996; Norton et al., 1996; Swamy-Mruthinti et al., 1996) , atherogenesis (Panagiotopoulos et al., 1998) and renal dysfunction in ageing rats (Reckelhoff et al., 1999) .
Aminoguanidine (pimegedine) has also been tested for the treatment of diabetic nephropathy in humans (Abdel-Rahman & Bolton, 2002) .
The aim of the present study was to determine whether administration of aminoguanidine attenuates the cardiac and vascular dysfunction in the DOCA-salt hypertensive rat, independent of changes in collagen content. This study has used a prevention protocol with oral administration of aminoguanidine following initiation of cardiovascular remodelling in DOCA-salt hypertensive rats. We have used echocardiography to define cardiac structure in vivo and the isolated Langendorff heart to define function ex vivo. Histological methods were used to define infiltration of inflammatory cells and collagen deposition. Isolated thoracic aortic rings were used to examine endothelial dysfunction. Microelectrode studies on isolated left ventricular papillary muscles were used to determine changes in cardiac action potentials. every fourth day (DOCA-salt rats). Rats were subsequently assigned into one of four groups:
MATERIALS AND METHODS

DOCA-salt hypertensive rats
(i) uninephrectomized controls (UNX)(n=21); (ii) uninephrectomized controls receiving 0.1% aminoguanidine in drinking water for 4 weeks (UNX+AG)(n=24); (iii) DOCA-salt hypertensive rats (DOCA)(n=29); and (iv) DOCA-salt hypertensive rats receiving 0.1% aminoguanidine in drinking water for 1 week, then 0.05% aminoguanidine in drinking water for 3 weeks (DOCA+AG)(n=31). All experiments were performed 4 weeks after uninephrectomy.
Assessment of physiological parameters
All rats for this study were housed separately. Food and water intake and body weights were measured daily for all rats. Daily aminoguanidine consumption was calculated from the daily water intake. Systolic blood pressure was measured in selected rats lightly sedated with intraperitoneal Zoletil® (tiletamine 15mg kg -1 with zolazepam 15mg kg -1 ). A tail pulse transducer (MLT1010) and an inflatable tail cuff were used, connected via a Capto SP844 physiological pressure transducer (MLT844/D) to a PowerLab data acquisition unit (ADInstruments, Sydney, Australia).
Echocardiographic Studies
Rats were anaesthetized with intraperitoneal injections of Zoletil® (tiletamine 25mg kg -1 and zolazepam 25mg kg -1 ) and xylazine (10mg kg -1 ) to produce anaesthesia with minimal cardiovascular depression. Serial, non-invasive, in vivo echocardiographic images were obtained using the Hewlett Packard Sonos 5500 echocardiography machine (12 MHz neonatal transducer) with an image depth of 3 cm and using 2 focal zones (Brown et al., 2002) . Left ventricular M-mode measurements at the level of the papillary muscles were used to obtain wall thicknesses. Suprasternal long axis views were used to obtain the internal diameters of the ascending aortic arch (Brown et al., 2002) .
Isolated Heart Preparations
The diastolic stiffness constant was determined using a non-recirculating isolated Langendorff heart preparation (Brown et al., 1999) . Briefly, rats were anaesthetized with sodium pentobarbitone (60mg intraperitoneal) and heparin (200 IU.kg -1 ) was administered via the femoral vein. After two minutes, the heart was rapidly excised and stunned in ice-cold (Brown et al., 1999) . To assess contractile function, maximum +dP/dT (rate of contraction) and -dP/dT (rate of relaxation) were calculated at a diastolic pressure of 10mmHg.
Histological studies of left ventricular collagen distribution, inflammatory cell infiltration and thoracic aortic wall thickness
Left ventricles (at mid-papillary level) and thoracic aortas were cut transversely, treated with
Telly's fixative and Bouin's solution and stained with picrosirius red as previously described (Allan et al., 2005; Fenning et al., 2005) . Thoracic aortic wall thicknesses were also measured using NIH-image software (National Institute of Health, USA). 
Microelectrode studies
Isolated left ventricular papillary muscles were prepared for microelectrode studies as previously described (Fenning et al., 2005) . After equilibration, action potential durations at 20%, 50% and 90% of repolarization were recorded from the papillary muscle over a 30-minute period, while continually being perfused with a drug-free Tyrode solution. Data were acquired, derived and analysed using Chart software (ADInstruments). (Brown et al., 1991) .
Isolated Thoracic Aortic rings
Cumulative concentration-response curves were performed for noradrenaline and either acetylcholine or sodium nitroprusside in the presence of a submaximal (approximately 70%) contraction to noradrenaline.
Statistical Analysis
All values are presented as mean ± standard error of the mean (SEM 
RESULTS
Physiological parameters
Daily aminoguanidine doses remained relatively constant over the 4 weeks with an average daily dose for UNX+AG rats of 97±4 mg kg -1 day -1 (n=16-28), and an average daily dose for DOCA+AG rats of 182±17 mg kg -1 day -1 (n=16-28) (Figure 1 ). DOCA-salt rats developed hypertension; aminoguanidine treatment significantly lowered systolic blood pressures in both UNX+AG and DOCA+AG groups (Table 1) .
Structural parameters
DOCA-salt rats exhibited marked cardiovascular remodelling, including left and right ventricular hypertrophy, increased left ventricular wall thickness, increased thoracic aortic wall thickness and decreased ascending aortic arch diameter but without dilatation of the left ventricular chamber (Table 1) . Furthermore, DOCA-salt rats showed increased left ventricular interstitial inflammatory cell infiltration together with left ventricular interstitial fibrosis (Table 1) . Treatment with aminoguanidine in the DOCA-salt rats attenuated the increase in left and right ventricular wet weights and prevented the decrease in ascending aortic arch diameter (Table 1) . Aminoguanidine did not significantly alter inflammatory cell infiltration or left ventricular fibrosis (Table 1) .
Functional parameters
DOCA-salt hypertensive rats exhibited significantly increased passive diastolic stiffness (Table 1) , reduced maximal rates of contraction and relaxation together with prolongation of the action potential durations at 20% and 90% of repolarization (Table 1) . Vascular dysfunction was also evident in the DOCA-salt rats as shown by reduced maximal contractile responses to noradrenaline and reduced maximal endothelium-dependent relaxation to acetylcholine and endothelium-independent relaxation to sodium nitroprusside (Figure 2 ).
Treatment with aminoguanidine in the DOCA-salt rats prevented the increased diastolic stiffness and improved rates of contraction and relaxation (Table 1 ). In addition, aminoguanidine increased action potential durations at 50% of repolarization but did not affect action potential durations at 20% and 90% of repolarization (Table 1) . Finally, aminoguanidine treatment prevented the decreased maximal vascular contractile and relaxant responses in the DOCA-salt hypertensive rats (Figure 2 ).
DISCUSSION
Long-lived proteins such as collagen undergo continual non-enzymatic cross-linking with advanced glycation end-products (AGEs) during ageing (Lakatta, 1993; Corman et al., 1998) as well as in diabetes (Brownlee, 1995; Norton et al., 1996) and hypertension (Mizutani et al., 2002; Wu & Juurlink, 2002) . Aminoguanidine inhibits the formation of collagen crosslinking by reacting with the reactive glucose-protein Amadori product and forming an unreactive substituted Amadori product that cannot form AGEs (Brownlee et al., 1986; Edelstein & Brownlee, 1992) . Increased collagen cross-linking has been shown to correlate with increased myocardial and vascular stiffness (Corman et al., 1998; Badenhorst et al., 2003) . Thus, inhibition of collagen cross-linking and AGE formation should decrease AGEinduced cross-linking and decrease stiffness. Aminoguanidine has additional actions that may be of relevance in the prevention of cardiovascular disease. It is a selective inhibitor of the endotoxin-induced or cytokine-induced inducible nitric oxide synthase (iNOS) isoform (Griffiths et al., 1993) . By inhibiting iNOS, aminoguanidine may also decrease the formation of peroxynitrite (Hong et al., 2000) , a pro-oxidant and an effective contributor to endothelial dysfunction (Kojda & Harrison, 1999) . Aminoguanidine may also act an as antioxidant in the DOCA-salt rat, a model of increased superoxide production (Somers et al., 2000; Wu et al., 2001) , by quenching hydroxyl radicals and inhibiting free radical formation (Giardino et al., 1998) . Further, AGEs binding to their receptor RAGE triggers a cascade of events leading to intracellular generation of free radicals, oxidative stress and activation of the transcription factor NF-κB (Yan et al., 1994; Lander et al., 1997) ; inhibition of AGE formation may prevent this cascade.
One possible mechanism of action of aminoguanidine in DOCA-salt rat hearts is as an iNOS inhibitor (Nilsson, 1999) . Inflammatory cell infiltration has been demonstrated in the left ventricles of DOCA-salt rats (Fujisawa et al., 2001; Ammarguellat et al., 2002) and iNOS has been implicated in inflammation (Salvemini et al., 1995) and myocardial dysfunction (Salvemini et al., 1995; Oyama et al., 1998) . However, it is important to note that as increased iNOS activity is characteristic of inflammation, a selective reduction in iNOS activity should also result in a reduction in inflammation. In this study, aminoguanidine did not reduce inflammatory cell infiltration into the myocardium, suggesting that iNOS inhibition by aminoguanidine is unlikely to be a major mechanism in the cardiac responses in the current study. The reduced response in thoracic aorta from UNX rats to acetylcholine could be due to inhibition of NO synthase in endothelial cells by aminoguanidine; however, this does not seem to apply to aorta from DOCA-salt rats where the endothelium is damaged.
The dosage of aminoguanidine used for this study was based on previous studies using 0.1% in the drinking water (Li et al., 1996; Reckelhoff et al., 1999) . Since dose depends on water intake, this protocol produced different doses to DOCA-salt and control (uninephrectomized) rats. However, a wide range of aminoguanidine doses has been reported (25mg kg -1 (Brownlee et al., 1986) , 100mg kg -1 (Kochakian et al., 1996) , 250mg kg -1 (Bucala et al., 1991) and 7.35mmol kg -1 (which as a free base equates to approximately 545mg kg -1 ) (Norton et al., 1996) ), all shown to be effective in inhibiting the formation of AGEs and cross-linking. Thus, it is likely that the average aminoguanidine dose administered in this study would be effective in inhibiting collagen cross-linking.
Most experimental studies have investigated the role of increased collagen cross-linking in ageing and diabetes, rather than in hypertension. An increased cross-linking was shown in DOCA-salt hypertensive rats (Ooshima & Midorikawa, 1977) and in Spontaneously
Hypertensive Rats (Badenhorst et al., 2003) but not in aortic-banded pressure overload hypertrophy (Badenhorst et al., 2003) . Methylglyoxal, the precursor of AGEs, and AGE formation were increased in the vascular tissues of Spontaneously Hypertensive Rats (Mizutani et al., 2002; Wu & Juurlink, 2002) ; inhibition of AGE formation lowered systolic blood pressure and glycated albumin concentrations (Mizutani et al., 2002) . As far as we are aware, this is the first study to show that a compound known to reduce collagen cross-linking can improve cardiac function in hypertensive rats.
Endothelial dysfunction is characteristic of the DOCA-salt rat (Kirchner et al., 1993; Somers et al., 2000) . Numerous studies have shown favourable effects of aminoguanidine on the vasculature of ageing and diabetic rats by decreasing cross-linking, reducing reactive oxygen species and inhibiting quenching of nitric oxide (Bucala et al., 1991; Li et al., 1996; Corman et al., 1998) . This study shows that this improvement can also be demonstrated in the DOCAsalt hypertensive rat. Changes in blood pressure as in the DOCA-salt hypertensive rat may lead to vascular remodelling to maintain the wall stress, according to the LaPlace relationship. An analysis of wall thicknesses at the operating pressure in treated and untreated rats, rather than in vitro in an isolated vessel, may allow estimation of changes in wall stress during treatment.
Action potential prolongation in hypertrophied DOCA-salt hearts is probably caused by a reduction in the transient outward potassium current (I to ) (Momtaz et al., 1996) . However, aminoguanidine appeared to have minimal effects on regulating potassium currents in our study. We have shown prolongation of the APD 50 in DOCA-salt rats treated with aminoguanidine. Prolongation of APD 50 is believed to be primarily due to an increased Ltype Ca 2+ inward current (I Ca ) (Hart, 1994) . Aminoguanidine has been shown to reverse the depression of the L-type calcium current in transplanted myocytes (Ziolo et al., 2001) . Thus, this could be one mechanism by which aminoguanidine treatment selectively prolonged APD 50 in these rats.
In summary, it is likely that inhibition of AGE-induced collagen cross-linking as well as its antioxidant properties contributed to the favourable effects of aminoguanidine on hypertension, hypertrophy, cardiac contractility and vascular reactivity without necessarily reducing fibrosis, inflammatory cell infiltration or iNOS activity in the DOCA-salt rats.
Furthermore, this study clearly supports the concept that improvement in function is not necessarily dependent on a reduced content of collagen but rather reduced collagen crosslinking. Indeed, if collagen cross-linking plays such an important role in hypertension, the use of selective AGE cross-link breakers such as ALT-711 (Vasan et al., 2003; Bakris et al., 2004) could be of significant therapeutic importance in reversing end-organ damage in hypertension. A recent study by Little and coworkers (2005) demonstrated that treatment with ALT-711 decreased left ventricular mass and improved left ventricular diastolic filling parameters and quality of life in patients with diastolic heart failure. Although experience with ALT-711 in clinical studies is still limited, this compound is a potential treatment for the symptoms of diastolic heart failure (Little et al., 2005; Redfield, 2005) . 123 ± 4 (6) 121 ± 5 (8) 157 ± 6* (7) 145 ± 5* (8) LVIDd (mm) 6.8 ± 0.2 (17) 7.1 ± 0.3 (13) 6.6 ± 0.2 (15) 6.6 ± 0.2 (15)
LV
Ejection fraction (%)
91.0 ± 1.5
92.6 ± 1.4 (13) 93.8 ± 0.9 (15) 93.3 ± 1.4 (15)
Ascending aortic arch diameter (mm)
3.3 ± 0.1 (7) 3.6 ± 0.1* (12) 2.9 ± 0.1* (5) 3.3 ± 0.1** (14) APD20 (msec) 6.8 ± 1.1 (8) 6.9 ± 1.1 (4) 10.1 ± 1.5* (7) 10.7 ± 1.0* (4)
APD50 (msec)
16.4 ± 2.0 (8) 22.8 ± 4.9 (4) 19.8 ± 2.7 (7) 42.4 ± 6.2** (4)
APD90 (msec)
34.4 ± 3.5 (8) 38.4 ± 7.7 (4) 59.1 ± 10.3* (7) 76.8 ± 11.2* (4)
All values shown represent the mean ± SEM (n value); LV=left ventricular, RV=right ventricular, LVPWd = left ventricular posterior wall thickness in diastole; LVIDd = left ventricular internal diameter in diastole; APD=action potential duration at 20, 50 or 90% of repolarization. Significance: *p < 0.05 vs UNX rats; **p < 0.05 vs DOCA-salt rats. Figure 2. Concentration-response curves to noradrenaline (A) for UNX rats (-log EC50 7.4±0.1, n=9), UNX rats treated with aminoguanidine (-log EC50 7.7±0.1, n=7), DOCA-salt rats (-log EC50 7.8±0.1, n=9) and DOCA-salt rats treated with aminoguanidine (-log EC50 8.0±0.1 n=7). Concentration-response curves to acetylcholine (B) for UNX rats (-log EC50 7.0±0.1, n=9), UNX rats treated with aminoguanidine (-log EC50 7.1±0.2, n=7), DOCA-salt rats (-log EC50 7.0±0.1, n=9) and DOCA-salt rats treated with aminoguanidine (-log EC50 7.6±0.2 n=7). Concentration-response curves to sodium nitroprusside (C) for UNX rats (-log EC50 7.8±0.1, n=9), UNX rats treated with aminoguanidine (-log EC50 7.7±0.1, n=7), DOCA-salt rats (-log EC50 7.4±0.1, n=9) and DOCA-salt rats treated with aminoguanidine (-log EC50 8.0±0.2 n=7). Values are mean±SEM; Significance: *p < 0.05 vs UNX rats; **p < 0.05 vs DOCA-salt rats. 
